Lawsuits accuse drugmakers, distributors of fueling US opioid crisis
Leading US pharmaceutical companies go on trial Monday charged with stoking the opioid epidemic that has ravaged American communities and left hundreds of thousands dead or overdosed across the country.
Tens of billions of dollars is at stake after last-minute efforts failed to agree a settlement between the companies and the states, counties, towns and native American tribes who have brought massive civil lawsuit.
The trial could be the most costly since litigation against tobacco companies in the 1990s, which showed cigarette companies cynically hiding and exploiting the dangers of tobacco for profits.
The plaintiffs in the first federal lawsuit in the opioid addiction crisis say manufacturers and distributors knew the dangers of the highly addictive painkillers they pumped into communities in the past 15 years, ignoring warning signs as they reaped billions in profits.
The trial in Cleveland, Ohio, pits 2,300 plaintiffs against giants of the pharmaceutical world, including drug distributors Cardinal Health, Amerisource Bergen, and McKesson Corp; Israel’s generic drug manufacturer Teva; and pharmacy chain Walgreen Boots Alliance.
Johnson & Johnson broke away with its own settlement, a $20.4 million deal with two of the worst-hit Ohio counties.
That came after Johnson & Johnson was ordered in August to pay $572 million to compensate Oklahoma state for the costs of dealing with the addiction crisis.
- Health systems overwhelmed -
In Ohio, Federal District Judge Dan Polster pressured all sides for months to come to a deal to avoid a grinding, lengthy trial.
But the parties could not come to an agreement on a proposed settlement valued at $48 billion, including $18 billion in cash, after meetings on Friday.
Four states involved in the litigation were in support.
But other states and many smaller litigants were dissatisfied with the amount, the size of the cash component, lawyers' fees and the way the money would be distributed.